Skip to main content
. 2022 Dec 15;13:1070379. doi: 10.3389/fimmu.2022.1070379

Figure 1.

Figure 1

Schematic workflow for the biomarker characterization in two cohorts of COVID-19 patients and two cohorts of controls (ALS and healthy). The two cohorts of COVID-19 patients analyzed in the study are COVID-19 patients admitted to the ICU ward Rianimazione 1 Fiera Milano COVID-19 (ICUCovid; n=79) and to COVID-19 wards ASST Papa Giovanni XXIII, Bergamo, with neurological complications (NeuroCovid; n=78). Blood samples were drawn acutely at ICU admission and after 7-14 days (T0-T14), and in the long-term between 15 and 90 days in the ward (T15-T90). Plasma samples were isolated and then analyzed for PPIA, MMP-9, GFAP, NFL, IL-10 and TNFα biomarkers. Control groups were ALS patients (n=51) and healthy subjects (n=20). Plasma samples were isolated and then analyzed for PPIA, MMP-9, GFAP and NFL.